Clinical trial · Observational
Oocyte Recovery During Tamoxifen Adjuvant Therapy
Tamoxifen as Adjuvant Treatment in Breast Cancer and Its Impact on Ovarian Function
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Survival in young patients with cancer has increased and also have increased the adverse long-term side effects of chemotherapy, there is a large number of women who experience loss of ovarian function without accomplishing their reproductive desire due to gonadotoxic treatment. The ovarian reserve determine the response to controlled ovarian hyperstimulation in fertility preservation treatments as well as in assisted reproduction techniques. Improving this reserve by avoiding its depletion during the process could result in increase fertility rates after cancer treatment. Collecting follicles during tamoxifen treatment would increase the number of cryopreserved oocytes and thus rise the potential ovarian reserve in these patients, which is reduced due to age, chemotherapy and length of treatments. The aim of this study is to retrieve viable mature oocytes during adjuvancy with tamoxifen in breast cancer patients to improve the probability of subsequent pregnancy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oocyte retrieval | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Metaphase II oocytes retrieved
- timeFrame
- 24 months
Secondary outcomes (3)
- measure
- Number of frozen embryos
- timeFrame
- 24 months
- measure
- Morphologic score of frozen embryos
- timeFrame
- 24 months
- measure
- Pregnancy rate
- timeFrame
- Expected average of 6 years
- description
- pregnancy rates after the use of frozen embryos generated during tamoxifen treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer patients whose tumors have positive hormone receptors (ER+) subsidiary of adjuvant treatment with tamoxifen * Reproductive desire Exclusion Criteria: * Having received chemotherapy agents less than 12 months ago * Current treatment with GnRH analogues * Age \> 35 years old * Contraindication for follicular punction or hCG administration
References
Publications (0)
Data not yet available